Yeah, I agree with your odds.
Re: label, I think approval for late-stage metastatic prostate cancer is basically a given. But the contention over labelling may be over whether it can be used early-stage, pre-treatment. There is significant impact on revenue between the two possible outcomes, but not disastrous. The broader label would eventually be granted after (presumably) more long-term safety data is provided.
Go time!, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.89 |
Change
0.370(2.11%) |
Mkt cap ! $5.986B | |||
| Open | High | Low | Value | Volume |
| $17.63 | $18.47 | $17.56 | $34.50M | 1.913M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3619 | $17.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.95 | 95 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |